US Stocks prediction

Consider the ledger:

• Shares Sold: 1,192,712 (enough to buy a small principality in the Principality of Sealand)
• Post-Transaction Holdings: 1,818,036 indirect shares (a kingdom once larger, now diminished) and 279,989 direct (a king’s ransom, yet a pittance for a man who once held 7 million)

The weighted average price-$5.76-suggests no desperation, merely the steady hand of a chessmaster moving pieces across a board where pawns become queens and queens become ghosts.

Trade direction: buy; position now represents 3.48% of the reported 13F assets under management. The long-term gambler watches, as the markets unfold like the slow march of time itself, witnessing new twists as old stakes are gradually raised.

According to a document filed with the Securities and Exchange Commission (a body whose primary purpose seems to be ensuring that paperwork remains the universe’s most enduring constant), Palisades had, during the third quarter, divested itself entirely of ADMA Biologics. This involved the sale of 398,647 shares, a number that sounds precise until you realize it’s roughly the population of a small island nation. The fund now holds precisely zero ADMA shares, a state of affairs as absolute as the heat death of the universe.

Weighted average price? A nice round $169.56 per share-now that’s a good day at the office.

Yet, let us not mistake ambition for substance. Upstart, though bold, remains a modest creature, its market cap a mere $4.5 billion-a pittance compared to the leviathan of Affirm. The stock, a ghost of its former self, lingers 88% below its peak, as if haunted by the specter of past misfortunes.

Beta measures price volatility relative to the S&P 500; figures use five-year monthly returns.

The fund’s retreat from Amkor, a 3.5% reduction in reportable AUM, now leaves it with a stake of 177,265 shares, worth $5.03 million. A modest sum, yet one that still commands 0.79% of the fund’s assets-a figure that, in the grand tapestry of finance, is neither thread nor tapestry.

On October 30, 2025, Elevation Capital Advisory executed what can only be described as a full retreat from ONEQ. The filing with the SEC revealed a complete liquidation of their position, leaving the fund with zero shares. For context, ONEQ had previously been 3.57% of their AUM. Now? A bold, if slightly panicked, zero. One wonders if they’re rebalancing or simply reacting to the market’s latest performance review.

The acquisition, equivalent to a 0.98% crescendo in their 13F AUM symphony, now positions Futu as the 1.94% whisper in their portfolio’s ear – a supporting role, not the leading man. The fund’s current holding of 47,988 shares, valued at $8.35 million, might seem modest to the vulgar eye, but to the connoisseur it speaks volumes of calculated restraint.

Picture this: Vantage had Floor & Decor in their portfolio at $90 a share. Now they’re selling it at $76. That’s like buying a brand-new Tesla and then trying to resell it at a yard sale. The fund’s Q3 2025 filing reveals they reduced their position from 1.28% of AUM to zero. For context, their top holdings now include United Health Group ($107.57M), Alphabet ($106.25M), and Nvidia ($62.01M). If I were FND, I’d be feeling the chill of a post-Thanksgiving clearance sale.